59 years old
Driving License
Dijon (21000)
Professional Status
Employed
Open to opportunities
About Me
Passionate about health and ethics issues, I had the chance with Pharmion and then Celgene to participate in the advent of immunotherapy by participating in the marketing in France of Imids from the beginning of the 2000s.
I wish to see the cure of an increasing number of cancers and I do this by promoting the Good Use of drugs with as much scientific rationale as possible, thus guaranteeing the best benefit/risk ratio for patients.
I wish to see the cure of an increasing number of cancers and I do this by promoting the Good Use of drugs with as much scientific rationale as possible, thus guaranteeing the best benefit/risk ratio for patients.
HOSPITAL PRODUCT SPECIALIST
Celgene
January 2008
to December 2018
- Management of 3 molecules. Management of proper use, drug safety, training.
Creation of projects in Burgundy, Franche-Comté & Champagne. (Azacitidine (SMD and LAM), Lenalidomide (SMD Del5q, MCL), Pomalidomide (multiple myeloma), focus on Pomalidomide in relapsed Myeloma. - Hospital Scientific Associate in myelodysplastic syndromes (MDS). Medical information and information on 5-azacitidine in myelodysplastic syndromes. Public relations. Project Manager.
Visit of professors and doctors in onco-hematology and oncology. - Creation of the Celgene Oncology Business Unit in France. My assignment was to monitor and report on the
safe use of Abraxane (Paclitaxel), indicated for the first-line treatment of pancreatic adenocarcinoma in Burgundy, Champagne and Franche-Comté. Education, public relations and medical information on 5-azacitidine in myelodysplastic syndromes for professors and physicians in onco-hematology as well as opinion leaders in MDS. - Education, public relations and medical information on 5-azacitidine in myelodysplastic syndromes for professors and physicians in onco-hematology as well as opinion leaders in MDS.
- **Results: **In the top 5 sectors, all products combined. Implementation of innovative and differentiating projects.